

WWW.FINANCIALEXPRESS.COM

FINANCIAL EXPRESS




μ	Anguary Factory Over 1	ZARTICUWARS
1	Name of the corporate digition along with FANA CRE (LP No.	We stat Pharmaceuticals provate Limit Prof. Arecszetth Color Units Units 2006/2016/Tich Units
2	Address of the registered office	44% Ground Floor, 15° Cross Malloyagara, Mallostatram, Inc. 15° Cross Malloyagara,
3.	URL of website	NA
4	Details of place where majority of fixed assets are focaled	Plot No: #37/A2, Pilagumpe, Hoskote, and existe, Bangalore, Karristaka, India, 562 114
5.	Installed capacity of main products/services	Any Interested PRA's can email us @smohema25@gmeit.com
6.	Quantity and value of main products/ services cold in the last financial year	ta
7.	Number employees' workmen	Ni m per the on available
8.	Further details including last evaluable francial statements (with schedules) of two last of caudium are available at URL:	
ů.	Eligibility for residution applicants under section 25(2)(h) of the Code is studiable at URL:	The documents can be obtained by sending an E-mail atampharma25@gmail.com
1U.	Last - le - receipt - expression of interest	01/11/2025
	Date of issue of provisional fiel of prospective resolution applicants	11/11/2025
12.	Last date for submission of objections to provisional test	16/11/2025
	Date of issue of final list of prospective resolution applicants	18/11/2025
14.	Date of issue of information memorandum, evaluation matrix and request for plans to prospective resolution applicants	23/11/2025
15	Last date for submission of resolution plans	22/12/2025
16.	Process emailed to submit EOI	sophama25@grat.com
17.	Details of the Corporate Datrica's registration status as MSME	UEAYAM: KR0280011321
For	any indomnation and clarification please Nethi Melikarjuna Setty on 996380644	Sd/- CA Nothi Multikarjuna Sela Resolution Professional o
	P	S.M. Pharmaceutica's Payalin Limited-In CIR
Da	te: 17/10/2025	No: IBB/IPA-001/IP-P01251/2018-2019/1195 AFA No: AA1/11958/02/3112/55/1074-5
Pia	ice: Hyderabad	AFA Valid up to 31/12/202

12 Fortis **FORTIS HEALTHCARE LIMITED**

Corporate Identity Number: L85110PB1996PLC045833 ad Office: Fortis Hospital, Sector 62, Phase - VIII, Mohali - 150052, Punjab TeL: +91-172-4692222, Fax: +91-172-5096221

NOTICE OF POSTAL BALLOT

Notice is heraby given that pursuant to the provisions of Section 108 and Section 110 of the Companies Act, 2013, read with the Companies Act, 2013 ("Lating Regulations."). Secretarial Standards on General Meeting Issuad by the Institute of Company Secretaries of India (SS-2) each as amended and in accordance with the guidelines prescribed by the Ministry of Corporate Affairs for hoking general meetings / conducting postal belief process, read with various General Circulars issued by the Ministry of Corporate Affairs bearing Circular No. 14/2020 dated April 3, 2020, 12/2020 deted dated April 3, 2020, 12/2020 deted dated April 3, 2020, 22/2020 deted dated April 3, 2020, 12/2020 dated December 3, 2021, 3/2022 dated May 5, 2022, 11/2022 dated December 3, 2021, 3/2022 dated December 3, 2022, 3/2022 dated Decem



The Board of Directors of the Company, at its Meeting held on October 15, 2025, approved the Standalone and Consolidated unaudited Financial Results for the quarter and half year

ended September 30, 2025. The results along with the Limited Paylow with the Limited Review Report, has been hosted on the Company's website at https://www.mrpl.co.in/Recent Result and can be accessed by scanning the Quick Response (QR) Code.

> By Dicter of the Board For Mangalore Relinery and Petrochemicals Limited Sd.1-Devendra Kumar Director Finance (DIM: 11000531)

Place : Manga Date: 15/10/2025

Nete: The above disclorure is in accordance with Regulation 33 read with Regulation 47(1) of the SEBI (Listing Obligation and Disclorure Regulations) Regulations, 2015.

NATIONAL STANDARD (INDIA)

CIN: L27109MH1962PLC285939
Regd. Office: 412, Floor- 4, 17G, Vardharnan Chamber, Cawasji Patel Road, Horniman
Website: www.nsil.net.in E-mail: Investors.nsil@odhagroup.com Tel.

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR TI HALF YEAR ENDED SEPTEMBER 30, 20

The Board of Directors of the Company at their meeting held on Octobe 16, 2025 approved the Unaudited financial results for the quarter and half year ended September 30, 2025.

The unaudited financial results of the Company along with the Limiter Review Report are available on the Stock Exchange's website a www.bseindia.com and Company's website at https://www.nsil.net.ir investor-relation/financial-result/financial-quarterty-2025-26 which cal be accessed by scanning the Quick Response Code.

> For and on behalf of the National St

Place: Mumbai Date: October 16, 2025

sement under Regulation 18 475 to better at Statut HYPERSOFT TECHNOLOGIES LIMITED Registered Office Unit 117, 1st Floor Turbour 2 by 5

tion of upon 42,25,442° Equity Stures of 8s.10/- each at an Offer Price per equity share of 8s.11/- each payable in cash, representing 26% of the expanded capital", pursue equilibition of Stares and Takeovers) Regulations, 2011 and subsequent amendments thereof, from the eligible public start excitodes of Hyperion (Technologies Limited) to by Mr. Narra Purna Bablo (the "Equiter") pursuant to Regulations 2(1), 3(2) and 3(3) Securities and Exchange Board of India Substantial Acquisition of Shares and Takeour

Includes 22,17,160 existing public shareholders as on the Public An

des 22,71,60 existing public, shareholders as on the Public Armouncament date.

Also 36,50,000 share allotted to officies in the public category pressum to the preferential issue which has been tocked in for a period of six months from the date of trading approved in acc COR) Regulations and are not permitted to be tendered in the open offer in accordance with regulation. In 7(2) of SERI LODR Regulations and if neddered, shall not be accepted in the open offer to except in the open offer to except the open of except the open offer to except the open offer to except the open of except the

Offer Price

The Offer Price is Rs. 11/- (Rupees Eleven Only) per Equity Share. There has been no revision in the Offer Price.

ndations of the Committee of Independent Directors of the Target Company:

The committee of independent directors of the Targel Company ("IDC") published its recom-believe that the Offer is fair and reasonable and in line with the SEBI SAST Regulations, 2011. endation on the Offer on 14th October, 2025 in the same newspapers where the DPS was publish

The Offer is not a competing offer in terms of Regulation 20 of SEBI SAST Regulations, 2011. There was no competing offer to the Offer and the last data for making such competing offer has exp any minimum level of acceptance in terms of Regulation 19(1) of SEBI SAST Regulations, 2011.

Despatch of Letter of Offer to the public shareholders.

DESPATION OF LECENCY OF THE WAY STATE OF THE WAY STATE OF THE GRAPH OF LECENCY OF THE WAY STATE AND THE CONTROL OF THE WAY STATE OF THE WAY ST ons to the public shareholders

5.1 In case the shares are held in physical form

in GSEC unesswers we have in projects from
Asper the provision or Regulation (ADI) of the SEBI (LODR) Regulations and SEBI's press refersed dated December 3, 2018, busing reference no. PM 49/2018, inquests for transfer or securities are held in dematterialised form with a depository with effect from April 1, 2019, However, in accordance with the Chapter 7 of SEBI Master circular issued by SEBI be artiCEPI/2023/31 dates february 16, 2023, abstrached fest helding securities in physical formare allowed to tender where are in an open offer. Such transfering shall be as per the peroreitors of the SEBI may perticipate in this Offer by approaching their respective SeBing Brider and tender their shares in the open offer as per the procedure as mentioned in the latest of Offer along with 1. In case the shares are held in demat form

5.2 In case the shares are held in demat form

An eligible shareholder may puricipate in this Offer by approaching their Selling Broker and tender their shares in the open offer as per the procedure as mentioned in the Letter of Offer.

5.3 Procedure For Fendering the Shares in case of Non-Receipt of the Letter of Offer.

5.3.1 Peopons who have sequined Equity-Shares but whose names do not appear in the register of members of the Target Company on the identified Date, or unregistered owners or those who have not received the Letter of Offer, may also participate in this Offer except Acquire; allottees in the public category pursuant to the preferential issue and Other Promote

5.3.2 In case of non-receiptor of the Letter of Offer, the Shareholders holding the Equity-Shares may puritipate in the Offer by proving their application in plain paper in writing signed by all sharehold

in case of physical shares: Name, address, distinctive numbers, folion ons, number of Equity-Shares tendered/withdrawn,

In case of dematerialized shares: Name, address, rumber of Equity-Shares tendered/withdrawn, DP D number, Beneficiary account no.,

In case of dematerialized shares: Name, address, rumber of Equity-Shares tendered/withdrawn, DP D number, Beneficiary account no.,

In case of demand shares, share, address, number of supers, superso, number of equity shares tendered/withdrawn, in case of demand shares share, address, number of Equity Shares tendered/withdrawn, or parame, pl D or umber, get Demands and one, and other relevant documents as mentioned in the Letter of Offer. Such Shareholders have to ensure that their order is entered fin the electronic platform of BSE through the Setting broker which closure of the fendering person.

Any other changes suggested by SER in their comments to be incorporated.

In terms of Regulation L6(1) of the SEBI SAST Regulations, 2011 the draft Letter of Offer was submitted to SEBI on 16° April, 2025 ("Draft Letter of Offer"). SEBI, wide its letter no. SEBI/HO/CFD dated 1.º October, 2025, issued its comments on the Draft Letter of Offer. These comments have been incorporated in the Letter of Offer. Any other material change from date of the Public Announcement

Any Corner frastrata change around the Trunck Announcement:
The Preferentialissue of Equity Shares by the Target Company was approved by the shareholders in the Extraordinary General meeting held on 26th April, 2025 and the Target Company has record, 2025 and the Target Company are Listed.

August, 2025 and trading approval on 24th September, 2025 from the Designated Stock Exchange- BSE Limited where shares of the Target Company are Listed.

August, 2023 and trading approval on 74th September, 2025 from the Designate distock Exchange—BSE Limited where shares of the Target Company are Listed.

Details regarding the status of the Sentancary and other approvals

As confirmed by the Acquirer, there are no statutory approvals required by the Acquirer to acquire the equity shares tendered pursuant to this Offer, However, in case of any statutory approval

later date before the closure of the tendering period, this Offer shall be subject to acquire the equity shares tendered pursuant to this Offer, However, in case of any statutory approval

in terms of Regulation 24.1 of the Self (SAST) Regulations, the Acquirer shall have the right to withdraw the Open Offer, in case of occurrence of any of the following conditions:

statutory approvals required for the open offer or ferfecting the acquisitions attracting the obligation to make an open offer under these regulations having been finally refused, subject to a

the acquirer, before a natural reservoir. In Acquirer than the control of the second of the period of the status o

The adquiret, using a natural person, inconsor, or any condition structure the obligation to make the open offer is not met for reasons outside the reasonable control of the acquiret, and such agreement for acquisition attracting the obligation to make the open offer is not met for reasons outside the reasonable control of the acquiret, and such agreement and the letter of offer, provided that an acquiret shall not withdraw an open offer pursuant to a public annount regulation (2) of regulation 13, even if the proposed acquisition through the preferential issue is not successful.)

ances as in the opinion of the Board, merit withdrawal.

In the event of such a withdrawal of the Open Offer, the Acquirer (through the Manager) shall, within 2 (two) Working Days of such withdrawal, make an announcement of such withdrawal sta

Schedule of Activities:

Florinal Cohadida of Arthritian for Analasad In